17 results about "Metastatic lesion" patented technology

This invention, belonging to the field of biological detection technology, discloses a marker and predictive diagnostic kit for luminal breast cancer bone metastasis based on circCCDC50 in tumor vesicles. Specifically, it discloses the use of circCCDC50 as a biomarker in the preparation of a product for the diagnosis / prediction of breast cancer bone metastasis. This invention proposes, for the first time, the use of circCCDC50 as a biomarker for luminal breast cancer bone metastasis. This circRNA can serve as a supplementary marker for the detection of luminal breast cancer bone metastasis and avoid missed detection of luminal breast cancer bone metastasis due to small metastatic lesions. circCCDC50 provides a broad and valuable predictive indicator for luminal breast cancer bone metastasis.

The application discloses a protein marker for predicting iodine uptake capacity of a thyroid cancer metastatic focus, a prediction method and a system, and belongs to the technical field of tumor medicine. The application provides 23 protein markers capable of being used for predicting iodine uptake capacity of a thyroid cancer metastatic focus, and the specific prediction method is as follows: the expression level of the protein marker in the metastatic focus tissue is obtained; the protein expression amount or abundance value is subjected to data preprocessing and standardization; the standardized protein expression amount is input into a pre-trained logistic regression model to obtain an iodine uptake positive probability value of the thyroid cancer metastatic focus, and the iodine uptake capacity of the sample is judged based on pre-determined classification threshold comparison. The method can depict iodine uptake related characteristics of the metastatic focus at a molecular level, provides an objective, quantifiable and reproducible iodine uptake capacity prediction scheme, provides an effective auxiliary basis for radioiodine treatment decision and patient risk stratification, and has clear application value and popularization significance.

This disclosure relates to a platelet-oncolytic virus complex, its preparation method, and its applications. The complex comprises platelets and oncolytic viruses, with the oncolytic viruses loaded within the platelets. The platelet-oncolytic virus complex utilizes the close interaction between platelets and circulating tumor cells (CTCs) to adhere to CTCs and directionally infect them with oncolytic viruses. By initiating oncolytic circulation, oncolytic viruses are continuously produced, clearing tumor cells from the circulatory system and metastatic lesions.

The invention relates to an ovarian cancer metastasis assessment local feature and global feature extraction method and device, which can improve the accuracy of ovarian cancer metastasis assessment, effectively prevent ovarian cancer metastasis and help medical personnel to discover lesions as soon as possible, so that effective treatment measures can be taken in time. The method comprises the following steps: (1) training and identifying seven key anatomical regions in an epigastric CT image; (2) performing multi-phase information fusion based on a multi-channel CNN encoder; (3) performing global feature learning and modeling on the multi-phase information by using Swin Transform, and processing the global information of the image; and (4) performing local feature learning on the multi-phase information by using a convolutional neural network (CNN), capturing detail information in each phase by using local feature extraction of the CNN, and extracting local texture, shape and edge information from the multi-phase medical image through convolution operation and nonlinear transformation.

This application belongs to the field of pharmaceutical formulation technology. This application discloses a multifunctional biomimetic nanoparticle formulation, its preparation method, and its application. The multifunctional biomimetic nanoparticle formulation of this application utilizes the dual functions of ginsenoside Rg3 as both a drug and a membrane stabilizer, as well as the natural targeting ability of platelet membranes to circulating tumor cells and metastatic lesions. Simultaneously, it utilizes cationic liposomes to adsorb negatively charged NETs nucleic acid protein complexes, achieving potential reversal and active targeting. Furthermore, by co-loading paclitaxel (PTX) and a photothermal agent (PCP), it integrates photothermal-chemotherapy-immunogenic death (ICD) induction functions, effectively inhibiting tumor-associated fibroblast activation, efficiently capturing circulating tumor cells, reshaping the tumor immune microenvironment, effectively killing tumor cells, and inhibiting distant tumor metastasis.

The application provides a double-layer biomimetic microneedle drug release system and a preparation method thereof, and belongs to the technical field of biological medicines.The application realizes programmed sequential release of inner-layer and outer-layer drugs by designing different properties of the inner-layer and outer-layer microneedle carrier materials.The application enhances the adhesion and hemostatic effect of the microneedle drug release device on the liver wound surface by designing a double-layer mushroom-shaped microneedle structure, improves the water solubility of hydrophobic therapeutic drugs by introducing drug-loaded particles, so that the therapeutic drugs can be used locally, and uses the microneedle to deliver the therapeutic drug-loaded particles to the disease tissue.Compared with traditional adjuvant therapy for preventing recurrence of liver primary tumors, the programmed sequential drug release device based on the microneedle can realize direct delivery of drugs to potential metastatic lesions, and avoids systemic adverse reactions caused by oral administration.Compared with local treatment methods such as transhepatic arterial intervention embolization and local radiotherapy, the double-layer biomimetic microneedle drug release system has the advantages of high targeting, small toxic and side effects, and convenient operation.

The present disclosure relates to the technical field of biological medicine, in particular to a polypeptide targeting PD-L1 and use thereof. The polypeptide provided by the present disclosure has high affinity and good stability. Based on the RDC of the polypeptide, the tumor primary lesion or metastatic lesion can be precisely targeted, and the polypeptide will not be retained in the tissues near the tumor and the tissues in non-tumor parts of the whole body, and the polypeptide can also avoid being rapidly degraded by proteases.

The invention provides a double-layer bionic microneedle drug release system and a preparation method thereof, and belongs to the technical field of biological medicine. According to the invention, by designing different properties of the microneedle carrier materials on the inner layer and the outer layer, programmed sequential release of the drugs on the inner layer and the outer layer is realized. By designing the double-layer mushroom-shaped microneedle structure, the adhesive force and the hemostatic effect of the microneedle drug release device on the liver wound surface are enhanced, the water solubility of the hydrophobic therapeutic drug is improved by introducing the drug-loading particles, so that the hydrophobic therapeutic drug can be locally used, and the therapeutic drug-loading particles are conveyed into disease tissues by using the microneedle. Compared with the traditional adjuvant therapy for preventing liver primary tumor recurrence, the programmed sequential drug release device based on the microneedle constructed by the invention can realize direct delivery of drugs to potential metastatic lesions, and avoids whole-body adverse reactions caused by oral administration of drugs. Compared with local treatment methods such as hepatic artery interventional embolism and local radiotherapy, the double-layer bionic microneedle drug release system has the advantages of high targeting property, small toxic and side effects, convenience in operation and the like.

The invention discloses a protein marker, a prediction method and a system for predicting iodine uptake capability of metastatic focus of cancer A, and belongs to the technical field of tumor medicine. The invention provides 23 protein markers capable of being used for predicting the iodine uptake capability of the thyroid cancer metastasis. The specific prediction method comprises the following steps: obtaining the expression level of the protein markers in metastasis tissues; performing data preprocessing and standardization on the protein expression quantity or abundance value; and inputting the standardized protein expression quantity into a pre-trained logistic regression model to obtain an iodine uptake positive probability value of the thyroid cancer metastatic focus, and comparing based on a predetermined classification threshold to judge the iodine uptake capability of the sample. According to the method, the related characteristics of iodine intake of the metastatic focus can be described on the molecular level, an objective, quantifiable and reproducible iodine intake ability prediction scheme is provided, an effective auxiliary basis is provided for radioiodine treatment decision and patient risk stratification, and the method has definite application value and popularization significance.

To provide a boron nanocarrier that enables treatment of a primary tumor by boron neutron capture therapy and also enables treatment of a metastatic lesion through immunostimulation.SOLUTION: There is provided a boron cluster which is capable of encapsulating a water-soluble protein and to which boron neutron capture therapy (BNCT) is applicable, wherein ortho-, meta-, or para-carborane derivatives represented by formulae (I-I) to (I-III) form a spherical, rod-like, or plate-like aggregate. In the formulae, a small black dot represents BH, and R1 and R2 each independently represent a hydrogen atom, a linear, branched, or cyclic saturated or unsaturated alkyl group, a phenyl group, a benzyl group, a naphthyl group, an anthracenyl group, a phenanthryl group, or the like, and may be the same as or different from each other.SELECTED DRAWING: None

Provided in the present invention is a bifunctional fusion protein radionuclide label, which has a high labeling yield and high radiochemical purity while maintaining high affinity and high functional activity, and has a suitable molecular weight, strong tissue penetration, a good imaging effect, a suitable circulation half-life, and strong molecular stability; the bifunctional fusion protein radionuclide label still has good affinity without being affected after radiolabeling a targeting carrier, has good biological metabolic activity and a good removal rate, and has reduced radiation toxicity, renal toxicity, hematological toxicity, and non-target organ toxicity; the bifunctional fusion protein radionuclide label has good enrichment in tumor cells, is conducive to implementing diagnosis and accurate staging of tumor lesions, and serves as a targeting carrier for implementing precision radiotherapy on primary lesions and metastatic lesions; and the bifunctional fusion protein radionuclide label has good safety and effectiveness potential, and has good application prospects in the field of solid tumor treatment.

The invention discloses a mouse model construction method for simulating intravenous injection circulating tumor cells, and belongs to the field of cell model construction. The invention discloses a method for constructing a tail vein injection circulating tumor cell mouse model for simulating lung metastasis of breast cancer. The method comprises the following steps: S1, treating a tumor operation specimen before transplantation; s2, constructing a PDX model mouse; s3, obtaining a circulating tumor cell suspension; s4, transplanting the circulating tumor cell suspension into the renal capsule of the immunodeficient mouse; s5, obtaining a tail intravenous injection circulating tumor cell mouse model for simulating the lung metastasis of the breast cancer; and S6, monitoring, verifying and evaluating the model. The problems that in the prior art, sources of circulating tumor cells are mixed, and deviation exists between the circulating tumor cells and actual conditions in clinic are solved, the goodness of fit between the circulating tumor cells and the clinical metastasis process is greatly improved, the number of metastases can be precisely regulated and controlled, and the reliability of data and the effectiveness of statistical analysis are ensured.

The invention provides application of a reagent for detecting a TUBA1B gene in preparation of a reagent for detecting non-small cell lung cancer bone metastasis and a stably transfected lung adenocarcinoma cell strain for low-expression and over-expression of the TUBA1B gene, and belongs to the technical field of lung cancer bone metastasis research. Single-cell sequencing data analysis is carried out on lung carcinoma in situ (PT), lung cancer bone metastasis primary lesion (MPT) and metastatic lesion (MT); screening differential genes as candidate genes, and then screening genes with significant difference in survival rate in lung adenocarcinoma in combination with a GEPIA2 database to obtain TUBA1B (Log2FC = 1.73, p < 0.05); according to the application, expression of the TUBA1B gene in lung adenocarcinoma cells A549 is interfered, knock-down or overexpression of the TUBA1B gene has remarkable influence on proliferation, invasion and migration capacities of the A549 cells, and an experimental foundation is laid for subsequent specific bone metastasis mechanism research.

The invention discloses a preparation method and application of a bimetallic composite nanomaterial for targeting a salivary gland adenoid cystic carcinoma tumor. The prepared bimetallic composite nanomaterial has SACC homologous targeting ability, and is used for systematically activating anti-tumor immune response of cold tumors. Under 808 nm laser irradiation, the nanometer material promotes active oxygen generation and glutathione depletion in tumor cells and aggravates oxidative stress by means of multi-enzyme activity and through photo-thermal therapy / photodynamic therapy / chemical dynamic therapy, generates oxygen to maintain PDT / CDT curative effect, effectively induces tumor cell immunogen cell death, and has a good application prospect. The adaptive anti-tumor immune response and cytotoxic T lymphocyte infiltration are obviously enhanced, so that the growth of primary lesion and metastatic lesion is inhibited. The invention provides an effective NIR-triggered space-time regulation and control system for reversing SACC cold tumor phenotype and inhibiting systemic metastasis.

This provides a novel therapeutic agent that can target HER2 in the brain parenchyma, transcending the blood-brain barrier (BBB). [Solution] In some embodiments, anti-HER2 constructs (e.g., Fc polypeptide dimer-antibody variable region fusion proteins) retain effector function upon binding to HER2 but do not substantially reduce reticulocytes in vivo. The disclosure also relates to methods for transcytosis of anti-HER2 antibody variable regions across the blood-brain barrier to treat HER2-positive cancers and their metastatic lesions.

The present application relates to the technical field of diagnosis and risk assessment of thyroid papillary carcinoma, and particularly relates to a composition, application and system for preoperative diagnosis and / or risk assessment of thyroid papillary carcinoma. The composition for preoperative diagnosis and / or risk assessment of thyroid papillary carcinoma comprises reagents for measuring the expression level of CLDN16 protein and / or the mRNA expression level of the gene encoding CLDN16 protein. Through the composition, the mRNA expression level of CLDN16 in thyroid tissue can be detected preoperatively, which is used for accurate diagnosis of the primary lesion and metastatic lesion of thyroid papillary carcinoma, and simultaneously, the disease risk of thyroid papillary carcinoma is accurately predicted to guide clinical decision-making.

The invention discloses a cancer diagnosis method and a cancer diagnosis system based on a large language model, which are characterized in that a comprehensive medical knowledge database is constructed by integrating multi-source medical data, and clinical data and image examination results of patients are deeply analyzed and comprehensively analyzed in combination with the powerful natural language processing capability of the large language model. The method comprises the following steps: firstly, converting clinical data into standardized medical terms by using a large language model, and preliminarily screening possible cancer types in a knowledge base; the range is further narrowed in combination with image features, and the positions of cancer stages, primary lesions and metastatic lesions are accurately judged; finally, the system generates personalized treatment suggestions of the next stage, and records diagnosis results to continuously optimize the accuracy of the system. According to the invention, the accuracy and efficiency of cancer diagnosis are improved, and more reliable and personalized medical services are provided for clinicians and cancer patients.